The combination of Gemcitabine plus nanoparticle albumin-bound (nab)-Paclitaxel (GA) have been evaluated as first line regimens for both metastatic pancreatic adenocarcinoma and breast cancer. The gene discussed is ALB; the disease is breast carcinoma.